HK1181613A1 - Macrocyclic compounds useful as inhibitors of histone deacetylases - Google Patents

Macrocyclic compounds useful as inhibitors of histone deacetylases

Info

Publication number
HK1181613A1
HK1181613A1 HK13108993.5A HK13108993A HK1181613A1 HK 1181613 A1 HK1181613 A1 HK 1181613A1 HK 13108993 A HK13108993 A HK 13108993A HK 1181613 A1 HK1181613 A1 HK 1181613A1
Authority
HK
Hong Kong
Prior art keywords
inhibitors
compounds useful
histone deacetylases
macrocyclic compounds
macrocyclic
Prior art date
Application number
HK13108993.5A
Other languages
English (en)
Chinese (zh)
Inventor
．劉
．菲利普斯
．安吉曼諾娃
．納斯威舒克
．張
Original Assignee
科羅拉多州立大學董事會，公司實體
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 科羅拉多州立大學董事會，公司實體 filed Critical 科羅拉多州立大學董事會，公司實體
Publication of HK1181613A1 publication Critical patent/HK1181613A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK13108993.5A 2010-05-27 2013-08-01 Macrocyclic compounds useful as inhibitors of histone deacetylases HK1181613A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34897810P 2010-05-27 2010-05-27
PCT/US2011/038246 WO2011150283A1 (fr) 2010-05-27 2011-05-26 Composés macrocycliques utiles comme inhibiteurs des histones déacétylases

Publications (1)

Publication Number Publication Date
HK1181613A1 true HK1181613A1 (en) 2013-11-15

Family

ID=45004403

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13108993.5A HK1181613A1 (en) 2010-05-27 2013-08-01 Macrocyclic compounds useful as inhibitors of histone deacetylases

Country Status (18)

Country Link
US (2) US8754050B2 (fr)
EP (1) EP2575467B1 (fr)
JP (1) JP5931850B2 (fr)
KR (2) KR20130123301A (fr)
CN (1) CN102946732B (fr)
AU (1) AU2011258110B2 (fr)
BR (1) BR112012030193B1 (fr)
CA (1) CA2800958C (fr)
DK (1) DK2575467T3 (fr)
ES (1) ES2594500T3 (fr)
HK (1) HK1181613A1 (fr)
HU (1) HUE030812T2 (fr)
LT (1) LT2575467T (fr)
MX (1) MX2012013507A (fr)
PL (1) PL2575467T3 (fr)
PT (1) PT2575467T (fr)
RU (1) RU2565076C2 (fr)
WO (1) WO2011150283A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102391359B (zh) * 2011-11-17 2014-07-16 南京优科生物医药研究有限公司 组蛋白去乙酰化酶抑制剂及其合成方法和制药用途
CN103232474A (zh) * 2013-04-16 2013-08-07 中国药科大学 组蛋白去乙酰化酶抑制剂
CN103524598A (zh) 2013-09-02 2014-01-22 上海冠宇生物医药科技有限公司 一类环肽类化合物、其制备方法、药物组合物及用途
CN106456613B (zh) * 2014-05-27 2019-07-09 恩库勒公司 制备环缩肽的方法
AU2016229324B2 (en) 2015-03-06 2020-01-16 Colorado State University Research Foundation Method for preparing largazole analogs and uses thereof
CA2978730A1 (fr) * 2015-03-06 2016-09-15 Colorado State University Research Foundation Synthese et utilisation de nouveaux analogues de largazole
CN105131082A (zh) * 2015-09-17 2015-12-09 广州康缔安生物科技有限公司 环肽类化合物及其应用
CN106674252B (zh) * 2015-11-11 2019-10-29 复旦大学 海洋天然产物环酯肽的氟代烯烃类似物、其制备方法和用途
US11203602B2 (en) 2016-05-20 2021-12-21 Onkure, Inc. Thioester prodrugs of macrocycles as inhibitors of histone deacetylases
CN107286223B (zh) * 2017-07-17 2019-12-20 湖北大学 一种用于检测组蛋白位点乙酰化的重组蛋白及其应用
CN111269245B (zh) * 2018-12-04 2021-08-27 杭州百新生物医药科技有限公司 一种环状氨基嘧啶衍生物及其抑制激酶的活性和用途
EP3865488A4 (fr) * 2018-12-19 2021-12-22 Keythera (Suzhou) Pharmaceuticals Co. Ltd. Composé macrocyclique servant d'inhibiteur de cdk, son procédé de préparation et son utilisation en médecine
WO2020190827A1 (fr) * 2019-03-21 2020-09-24 Merck Sharp & Dohme Corp. Inhibiteurs d'histone désacétylase utiles pour le traitement ou la prévention d'une infection par le vih
KR102436309B1 (ko) * 2020-05-26 2022-08-25 연세대학교 산학협력단 암의 예방 또는 치료용 약학적 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8920304D0 (en) 1989-09-08 1989-10-25 Fujisawa Pharmaceutical Co Fr901375 substance and preparation thereof
WO2004020460A1 (fr) * 2002-08-30 2004-03-11 Yamanouchi Pharmaceutical Co., Ltd. Nouveau compose depsipeptide
CA2504226A1 (fr) * 2002-11-12 2004-05-27 Alcon, Inc. Inhibiteurs d'histone deacetylase destines au traitement de maladies degeneratives de l'oeil
US20060128660A1 (en) * 2004-12-10 2006-06-15 Wisconsin Alumni Research Foundation FK228 analogs and methods of making and using the same
JP5178731B2 (ja) * 2006-11-22 2013-04-10 カルス セラピューティクス リミテッド デプシペプチドおよびその治療的使用
GB0623388D0 (en) * 2006-11-23 2007-01-03 Univ Southampton Chemical compounds
GB0715750D0 (en) * 2007-08-13 2007-09-19 Karus Therapeutics Ltd Chemical compounds
AU2009234398B2 (en) 2008-04-11 2015-01-22 University Of Florida Research Foundation, Inc. Macrocyclic compounds and methods of treatment
WO2010009334A1 (fr) * 2008-07-17 2010-01-21 Colorado State University Research Foundation Procédé de préparation d’analogues de largazole et ses utilisations
CN102391359B (zh) * 2011-11-17 2014-07-16 南京优科生物医药研究有限公司 组蛋白去乙酰化酶抑制剂及其合成方法和制药用途

Also Published As

Publication number Publication date
US20130203681A1 (en) 2013-08-08
CN102946732B (zh) 2014-11-26
AU2011258110B2 (en) 2015-07-16
AU2011258110A1 (en) 2013-01-10
BR112012030193A2 (pt) 2015-09-29
BR112012030193B1 (pt) 2020-11-17
RU2012157293A (ru) 2014-07-10
US20150010541A1 (en) 2015-01-08
KR20130123301A (ko) 2013-11-12
CA2800958C (fr) 2018-09-04
US9422340B2 (en) 2016-08-23
US8754050B2 (en) 2014-06-17
KR102028850B1 (ko) 2019-10-04
LT2575467T (lt) 2017-01-10
HUE030812T2 (en) 2017-05-29
JP2013528182A (ja) 2013-07-08
EP2575467A1 (fr) 2013-04-10
ES2594500T3 (es) 2016-12-20
DK2575467T3 (en) 2016-09-26
JP5931850B2 (ja) 2016-06-08
RU2565076C2 (ru) 2015-10-20
EP2575467B1 (fr) 2016-07-06
PL2575467T3 (pl) 2017-10-31
MX2012013507A (es) 2013-03-12
EP2575467A4 (fr) 2014-10-15
WO2011150283A1 (fr) 2011-12-01
PT2575467T (pt) 2016-10-14
CA2800958A1 (fr) 2011-12-01
KR20180081153A (ko) 2018-07-13
CN102946732A (zh) 2013-02-27

Similar Documents

Publication Publication Date Title
HK1259135A1 (zh) Vmat2的苯並喹啉酮抑制劑
HK1181613A1 (en) Macrocyclic compounds useful as inhibitors of histone deacetylases
ZA201707157B (en) Multisubsituted aromatic compounds as inhibitors of thrombin
ZA201700326B (en) Inhibitors of beta-secretase
IL237581B (en) Derivatives of 6-oxo-pyrazinopyrrolopyrimidines
EP2701699A4 (fr) Inhibiteurs de l'histone désacétylase
HK1176616A1 (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6 cdk4/6
HK1178149A1 (en) Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use -4---
IL221823A (en) Pipridine-4-Il-Aztidine Derivatives as Jack 1 Suppressors
EP2584903A4 (fr) Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
PL3255114T3 (pl) Zastosowanie kompozycji do chłodzenia
EP2539348A4 (fr) Dérivés de la céphalosporine utiles comme inhibiteurs de la -lactamase et leurs compositions et procédés d'utilisation
ZA201206456B (en) Uses of dgati inhibitors
IL218018A0 (en) Novel n-substituted-pyrrolidines as inhibitors of mdm2-p-53 interactions
ZA201208895B (en) Bicyclic compound derivatives and their use as acc inhibitors
SG2014013460A (en) Monohydrate of an azaadamantane derivative
IL222313A0 (en) Combination of organic compounds
EP2531197A4 (fr) Formes à l'état solide d'inhibiteurs macrocycliques de kinases
EP2579872A4 (fr) Inhibiteurs de l'activité akt
IL225708A0 (en) Methods for the synthesis of scylitol and related compounds
GB2492717B (en) Detecting no progress state of an application
EP2543373A4 (fr) Composition pharmaceutique de composé de levoamlodipine
LU91725B1 (en) Novel uses of V-ATPASE inhibitors
HK1160443A1 (en) Histone deacetylase inhibitors
GB201010671D0 (en) Compounds for treatment of inflammation